• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community

    9/5/24 8:30:00 AM ET
    $CTCX
    Medical/Dental Instruments
    Health Care
    Get the next $CTCX alert in real time by email

    PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced a strategic partnership with Ladies Playbook, an exclusive community dedicated to providing support, information, and the connections for an NFL family to thrive wherever their football career takes them.

    The NFL is the most valuable sports franchise in the world, with annual revenues approaching $20 billion from 32 teams, collectively worth approximately $160 billion, according to Statista.

    This partnership comes as the new NFL season kicks into full gear and as Carmell aims to accelerate the growth of its flagship brand, Carmell Secretome™, through the expansion of its direct-to-consumer and e-commerce customer channels as well as driving toward influential franchise initiatives like Ladies Playbook. Carmell Secretome™ is a new approach to regenerative skincare and haircare that consists of a potent cocktail of proteins, peptides and bio-lipids extracted from allogeneic human platelets without the use of synthetic proteins.

    "After spending 11 years in the NFL, I created Ladies Playbook as a space to help other women find all their needs conveniently in one place. Our partnership with Carmell enables NFL Ladies an opportunity to enhance their own skin health through bio-aesthetic derived products and the local MedSpa community," said Atoya Burleson, Founder of Ladies Playbook.

    Through this partnership, Carmell will showcase its commitment to skin health and education by hosting a series of events with key wives and girlfriends from the NFL community in various markets from Seattle, Minnesota, Miami and New York. Furthering its commitment, Carmell and Ladies Playbook will also build omni-channel opportunities to feature both brands across social media, ladiesplaybook.com, carmellsecretome.com and digital platforms leading to the Ladies Playbook Awards in New Orleans – Super Bowl LIX.

    "We understand the importance of skin health and its impact on internal systems that are imperative to our overall health and well-being, many of the ambassadors are playing within their homes. The alignment between our brands is rooted in our focus on a revolutionary approach to regenerative skincare that utilizes human biology vs. synthetic chemistry to target the five pathways of skin aging to support skin and hair health. While our technology is impressive, what's equally impressive is what is not in the bottle. In our goal for Carmell Secretome™ to be the best skincare in the market, we developed a list of 14 excipients that will never be found in our products. We call them The Foul Fourteen™. By excluding these excipients from our products, we ensure our products are just as nature intended and nothing more. From being on the field, to traveling between games, running their own businesses and more, we are excited to provide products to the Ladies Playbook community to support skin health with no harsh chemicals, no pore-clogging goo, no artificial dyes and no fake fragrances," said Kendra Bracken-Ferguson, Chief Executive Officer of Carmell.

    About Carmell

    Carmell is a bio-aesthetics company that utilizes the Carmell Secretome™ to support skin and hair health. The Carmell Secretome™ consists of a potent cocktail of proteins, peptides and bio-lipids extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past seven years, the Company has extensively tested the technology underpinning the Carmell Secretome™. Additionally, the Company has developed a novel microemulsion formulation that enables the delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen™, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. The Company is also developing a line of men's products and a line of topical haircare products. All products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. For more information, visit www.carmellcosmetics.com.

    Forward-Looking Statements

    This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the launch and commercialization of our products, our expected cash runway, our potential acquisition and investment activity, the anticipated benefits of future acquisitions and investments, our projected future results and market opportunities, our expected growth and ability to achieve profitability, the expansion of our product portfolio and the execution of our business strategy. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, those described under the header "Risk Factors" in the Annual Report on Form 10-K filed by Carmell with the SEC on April 1, 2024, as amended by the Annual Report on Form 10-K/A filed with the SEC on April 29, 2024, and in our other reports filed with the SEC. Most of these factors are outside of Carmell's control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

    Contact:

    Bryan Cassaday, CFO

    [email protected]



    Primary Logo

    Get the next $CTCX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CTCX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CTCX
    Leadership Updates

    Live Leadership Updates

    See more
    • CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

      Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

      3/10/25 8:30:00 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

      PITTSBURGH, July 29, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Company" or "Carmell"), today announced the appointment of Ms. Kendra Bracken-Ferguson as Chief Executive Officer effective July 30, 2024 with Mr. Rajiv Shukla continuing to serve as Executive Chairman of the Company. Kendra's appointment comes at a pivotal moment of growth for the Company. Since its business combination in July 2023, the Company has completed a pivot towards skincare, recruited a top-tier Scientific Advisory Board, developed and tested 12 skincare products aimed at retail and medspa use, scaled up in-house manufacturing and packagi

      7/29/24 8:30:00 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

      PITTSBURGH, March 20, 2024 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the execution of a definitive agreement to sell its wholly owned subsidiary, Axolotl Biologix ("AxoBio") to the initial sellers of AxoBio for 3,845,337 shares of Carmell common stock, 4,243 shares of Carmell preferred stock and notes payable to the initial sellers in the aggregate amount of $8 million. "The sale of AxoBio enables our exit from the tissue graft space thereby facilitating a sharper organizational focus on the launch of our skincare products beginning in March 2024 and co

      3/20/24 4:39:36 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    SEC Filings

    See more

    $CTCX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 424B3 filed by Carmell Corporation

      424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

      3/26/25 5:01:17 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Longevity Health Holdings, Inc. (0001842939) (Filer)

      3/26/25 5:00:09 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 424B3 filed by Carmell Corporation

      424B3 - Longevity Health Holdings, Inc. (0001842939) (Filer)

      3/10/25 8:53:40 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Bracken-Ferguson Kendra

      4 - Carmell Corp (0001842939) (Issuer)

      11/8/24 5:13:51 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Gregory Kathryn

      4 - Carmell Corp (0001842939) (Issuer)

      11/8/24 5:00:05 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Cassaday Bryan J.

      4 - Carmell Corp (0001842939) (Issuer)

      11/8/24 5:00:12 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CARMELL CORP REBRANDS AS LONGEVITY HEALTH HOLDINGS TO HIGHLIGHT BUSINESS FOCUS & GROWTH STRATEGY

      Pittsburgh, PA, March 10, 2025 (GLOBE NEWSWIRE) -- PITTSBURGH, Mar. 10, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX, CTCXW)), a bio-aesthetics company (the "Company", "we", "our", or "us"), today announced a comprehensive corporate rebranding initiative aimed at better aligning the Company's market and investor facing image with its business focus and growth strategy. As part of the rebranding, the Company has changed its corporate name to "Longevity Health Holdings, Inc." and, at the open of trading on March 10, 2025, the Company's common stock and redeemable warrants will begin trading under the symbols "XAGE" and "XAGEW", respectively. The Company has also launc

      3/10/25 8:30:00 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Announces Closing of Elevai Skincare Acquisition

      PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. ("Elevai"), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) ("PMGC") and Elevai, its wholly owned subsidiary (the "Acquisition"). At the closing of the Acquisition (the "Closing"), the purchase consideration consisted of the following: Approximately $1.1 mill

      1/16/25 8:00:28 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Carmell Announces Closing of Previously Announced PIPE Investment from Existing and New Investors to Support Commercial Build-out

      PITTSBURGH, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (NASDAQ:CTCX), a bio-aesthetics company focused on skin and hair health ("Carmell", the "Company", "we", "our", or "us"), today announced the closing of its previously announced private placement with new and existing investors pursuant to a securities purchase agreement, dated December 23, 2024, for the issuance and sale of 8,065,210 shares of its common stock and an equal number of five-year warrants both priced at $0.23 per share, in a private placement for aggregate gross proceeds of $1.85 million before deducting offering expenses and fees (the "Private Placement"). The Private Placement was priced at a slight premium t

      1/3/25 8:00:03 AM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Carmell Corporation

      SC 13G/A - Carmell Corp (0001842939) (Subject)

      12/6/24 4:16:05 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Carmell Corporation

      SC 13G/A - Carmell Corp (0001842939) (Subject)

      11/14/24 2:48:40 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Carmell Corporation (Amendment)

      SC 13G/A - Carmell Corp (0001842939) (Subject)

      4/18/24 3:03:07 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care

    $CTCX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Upton Richard A bought $2,336 worth of shares (5,000 units at $0.47), increasing direct ownership by 50% to 15,000 units (SEC Form 4)

      4 - Carmell Corp (0001842939) (Issuer)

      9/16/24 4:30:07 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Director Frisch Scott M. bought $515 worth of shares (1,009 units at $0.51) (SEC Form 4)

      4 - Carmell Corp (0001842939) (Issuer)

      9/10/24 4:30:11 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care
    • Director Gregory Kathryn bought $643 worth of shares (1,260 units at $0.51) (SEC Form 4)

      4 - Carmell Corp (0001842939) (Issuer)

      9/10/24 4:30:16 PM ET
      $CTCX
      Medical/Dental Instruments
      Health Care